TPTanmay K. Pati

Tanmay K. Pati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tanmay K. Pati has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain

    by Christopher L. Cioffi, Tanmay K. Pati, Irina Lotsaris, Srinivasan Jayakumar, Julian Peiser-Oliver, Gaddam Mahesh, Ryan P. Cantwell Chater, Aravindan Jayaraman, Zachary J. Frangos, Krishna Suleria, et al.

    Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2–/–) mice. To address these challenges, we developed a series of second-generation, conformationally restricted indoline analogues that act as noncompetitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, nonopioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.

  • Open Access

    Identification of Non-Competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-Opioid Therapeutic Strategy for Neuropathic Pain

    by Christopher Cioffi, Tanmay Pati, Irina Lotsaris, Srinivasan Jayakumar, Julian Peiser-Oliver, Gaddam Mahesh, Ryan Cantwell Chater, Aravindan Jayaraman, Zachary Frangos, Krishna Suleria, et al.

    Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2-/-) mice. To address these challenges, we developed a series of sec-generation, conformationally restricted indoline analogues that act as non-competitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, non-opioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.

  • Open Access

    A reversible allosteric inhibitor of GlyT2 alleviates neuropathic pain without on-target side effects

    by Ryan P. Cantwell Chater, Julian Peiser-Oliver, Tanmay K. Pati, Ada S. Quinn, Irina Lotsaris, Zachary J. Frangos, Kristen E. Anderson, Anna E. Tischer, Billy J Williams-Noonan, Karin R. Aubrey, et al.

    Chronic neuropathic pain, caused by nerve damage or disease, is increasing in prevalence, but current treatments are ineffective and over-reliant on opioids. The neuronal glycine transporter, GlyT2, regulates inhibitory glycinergic neurotransmission and represents a promising target for new analgesics. However, most GlyT2 inhibitors cause significant side effects, in part due to irreversible inhibition at analgesic doses. Here we develop a reversible inhibitor of GlyT2, RPI-GLYT2-82, and identify its binding site by determining cryo-EM structures of human GlyT2. We capture three fundamental conformational states of GlyT2 in the substrate-free state, and bound to either glycine, RPI-GLYT2-82 or the pseudo-irreversible inhibitor ORG25543. We demonstrate that RPI-GLYT2-82 dissociates from GlyT2 faster than ORG25543, providing analgesia in mouse neuropathic pain models without on-target side-effects or addiction liability. Our data provide a mechanistic understanding of allosteric inhibition of glycine transport, enabling structure-based design of non-opioid analgesics.


  • RuII–Catalyzed C–H Activated Diverse Cyclization with Transformation of Substrate-DG to Functional Groups: Synthesis of Functionalized Indoles and Indenones

    by Ramlal Baidya, Saikat Khamarui, Sabir A. Molla, Pintu Pratihar, Prasenjit Das, Tanmay K. Pati, Dilip K. Maiti

    We present an elegant and efficient method for Ru(II)-catalyzed C-H activation, followed by a diverse range of intermolecular cross-dehydrogenative coupling reactions. This process is facilitated by an intrinsic directing group (DG) and includes the in situ transformation of the DG into common and useful functional groups. Notably, this method avoids the installation and deinstallation of the directing group. Our approach enables the selective functionalization of benzimidate, coupled with the cyclization of o-alkynyl-aniline, resulting in the high-yield synthesis of diverse compounds such as indoles, and indenones. The sequential formation of C-N, C-C, and C-O bonds, followed by hydrolysis, underscores the versatile in situ transformation of the directing group. This work not only broadens the synthetic toolbox for constructing complex heterocyclic structures but also highlights the potential for sustainable and selective synthesis of valuable compounds.